Mesoblast, COVID-19 And Trump?
As an analyst who follows biopharma companies, I take an interest in the US Food and Drug Administration (FDA), while as an American/Australian, US politics, particularly, in the days of Trump, is also an interest. Then, there is an ASX-listed cellular therapy company called Mesoblast (ASX:MSB), which I have followed pretty much since it listed in 2004.
Read More